Mode
Text Size
Log in / Sign up
N/A Completed N=588 Randomized Double-blind Treatment

A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee

Osteoarthritis, Knee
Source: ClinicalTrials.gov NCT00379236 ↗
Enrolled (actual)
588
Serious AEs
3.0%
Results posted
Dec 2009
Primary outcomePrimary: Observed Pain Scores on 50-foot Walk Test During the Double-blind Study — 55.6; 54.7; 30.0; 36.1 units on a scale

Summary

This multicenter, randomized, double-blind study will be performed in approximately 600 subjects with chronic idiopathic osteoarthritis (OA) of the knee. An open-label safety extension will follow.

Outcome Measures

OutcomeResultp-value
PRIMARY
Observed Pain Scores on 50-foot Walk Test During the Double-blind Study
55.6; 54.7; 30.0; 36.1 —
PRIMARY
Percent Change From Baseline in Observed Pain Scores on 50-foot Walk Test During the Double-blind Study
-30.9; -14.9 0.002 sig
PRIMARY
Shifts From Extension Study Baseline (Week 26) in Range of Motion Findings at Week 52
76; 33; 6; 0; 42; 171 —
PRIMARY
Shifts From Extension Study Baseline (Week 26) in Ratings of Knee Tenderness at Week 52
129; 44; 5; 0; 61; 75 —
PRIMARY
Shifts From Extension Study Baseline (Week 26) in Ratings of Knee Local Warmth at Week 52
2; 11; 11; 353 —
PRIMARY
Shifts From Extension Study Baseline (Week 26) in Ratings of Knee Redness at Week 52
0; 0; 4; 373 —
SECONDARY
Percent Change From Screening in Observed Pain Scores on 50-foot Walk Test During the Double-blind Study
-29.3; -38.4 0.008 sig
SECONDARY
Percent Change From Baseline in Observed Pain Scores on 50-foot Walk Test During the Double-blind Study for a Subpopulation of Participants With More Severe Knee Pain
-50.5; -36.8 0.001 sig
SECONDARY
Number of Observed Osteoarthritis Research Society International (OARSI30) Responders Using the 50-Foot Walk Test at Week 12
173; 167; 90; 107 0.202
SECONDARY
Number of Observed Osteoarthritis Research Society International (OARSI30) Responders Using the 50-Foot Walk Test at Week 26
169; 155; 85; 109 0.047 sig
SECONDARY
Number of Observed Osteoarthritis Research Society International (OARSI30) Responders Using the Western Ontario McMaster University Osteoarthritis Index (WOMAC A) Pain Scale at Week 12
153; 155; 109; 118 0.618
SECONDARY
Number of Observed Osteoarthritis Research Society International (OARSI30) Responders Using the Western Ontario McMaster University Osteoarthritis Index (WOMAC A) Pain Scale at Week 26
155; 137; 98; 127 0.028 sig
SECONDARY
Change From Baseline in Patient Global Assessment of Knee Pain at Week 26
-22.0; -17.8 —
SECONDARY
Change From Baseline in the Number of Tablets of Rescue Medication Used at Week 26.
12.7; 12.9 —
SECONDARY
Mean Change From Baseline in Short Form 36 Questionnaire (SF-36) Physical Function (PF) Score at Week 26
4.77; 3.18 —
SECONDARY
Mean Change From Baseline in Short Form 36 Questionnaire (SF-36) Bodily Pain(BP) Score at Week 26
3.85; 2.94 —
SECONDARY
Mean Change From Baseline in Short Form 36 Questionnaire (SF-36) General Health(GH) Score at Week 26
1.38; 0.19 —
SECONDARY
Mean Change From Baseline in Short Form 36 Questionnaire (SF-36) Physical Component Summary (PCS) Score at Week 26
4.55; 2.71 —
SECONDARY
Number of Participants With 20 Millimeter or Greater Improvement in Pain Scores on the 50-foot Walk Test
145; 120; 106; 139 0.006 sig
SECONDARY
Observed Pain Scores on the 50-foot Walk Test During the Extension Study
33.1; 24.7 —
SECONDARY
Mean Change From Baseline in Observed Pain Scores on 50-foot Walk Test During the Extension Study
-7.8 —
SECONDARY
Number of Observed Osteoarthritis Research Society International (OARSI30) Responders Using the 50-Foot Walk Test at Week 52
144; 230 —
SECONDARY
Change From Baseline (Extension Study Week 26) in Use of Rescue Medication at Week 52.
9.5 —

Eligibility Criteria

Inclusion Criteria

  • Chronic OA of target knee confirmed by ACR Criteria
  • Pain due to OA in target knee present for at least 6 months:
  • Moderate to severe pain score of 41 mm to 90 mm recorded on a 100 mm VAS immediately following a 50-foot walk
  • A bilateral standing AP X-ray confirming OA of the target knee-obtained within a 6-month period prior to the Screening Visit-and a grade of 2 or 3 according to the Kellgren and Lawrence Grading Scale
  • Ability and willingness to use only acetaminophen as the analgesic (rescue) study medication
  • The acetaminophen dose must not exceed 4 grams/day (4000 mg)
  • If subject has known chronic liver disease, the maximum dose of acetaminophen must not exceed 2 grams/day (2000 mg)
  • The subject must be willing and able to discontinue acetaminophen at least 24 hours prior to all study-specific visits
  • The study specific acetaminophen provided will only be used for knee pain.
  • Ability to perform procedures required of the pain index evaluations (unassisted walking 50 feet on a flat surface and going up and down stairs).
  • Willingness and ability to complete efficacy and safety questionnaires and ability to read and understand study instructions
  • Signed study-specific Subject Informed Consent Form

Exclusion Criteria

  • Any major injury (including sports injuries) to the target knee within the 12 months prior to the Screening Visit
  • Any surgery to the target knee within the 12 months prior to the Screening Visit, or surgery to the contralateral knee or other weight-bearing joint if it will interfere with knee assessments
  • Prior articular procedures, such as transplants or ligament reconstruction to the target knee
  • Inflammatory arthropathies such as rheumatoid arthritis, lupus arthropathy, or psoriatic arthritis
  • Gout or calcium pyrophosphate (pseudogout) diseases that have flared within the previous 6 months prior to the Screening Visit
  • X-ray findings of acute fractures, severe loss of bone density, avascular necrosis, and/or severe bone or joint deformity in the target knee
  • Osteonecrosis of either knee
  • Fibromyalgia, pes anserine bursitis, lumbar radiculopathy, and/or neurogenic or vascular claudication
  • Significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or chondromalacia in the target knee
  • Significant target knee joint infection or skin disorder/infection within the previous 6 months prior to study enrollment
  • Symptomatic OA of the hips, spine, or ankle, if it would interfere with the evaluation of the target knee
  • Known hypersensitivity to acetaminophen, EUFLEXXA™, or Phosphate buffered saline solution
  • Women of childbearing potential who are pregnant, nursing, or planning to become pregnant, and those who do not agree to remain on an acceptable method of birth control throughout the entire study period
  • Recurrent medical history of severe allergic or immune-mediated reactions or other immune disorders
  • Vascular insufficiency of lower limbs or peripheral neuropathy severe enough to interfere with the study evaluation
  • Current treatment or treatment within the previous 2 years prior to the Screening Visit for any malignancy unless specific written permission is provided by the Sponsor (excluding basal cell or squamous cell carcinoma of the skin)
  • Active liver disease based on liver profile of AST, ALT, and conjugated bilirubin >2 times the upper limit of normal
  • Renal insufficiency based on serum creatinine >2.0 mg/dL
  • Any clinically significant laboratory value based on clinical history that the Investigator feels may affect the study evaluation
  • Any intercurrent chronic disease or condition that may interfere with the completion of the 6-month (or 12-month) follow-up of the study, such as liver disease, severe coronary disease, drug abuse, disordered mental state, or other clinically significant condition
  • Current alcoholism, and/or any known current addiction to pain medications
  • Any c
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00379236). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search